These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 30654067)

  • 1. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of a decentralized, nurse-led, statewide model of care for hepatitis C among people in prison in Victoria, Australia.
    MacIsaac MB; Papaluca T; McDonald L; Craigie A; Edwards A; Layton C; Gibson A; Winter RJ; Iyer K; Sim A; Evans S; Kumaragama K; Howell J; Desmond P; Iser D; Scott N; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Holmes JA; Thompson AJ
    Clin Infect Dis; 2024 Sep; ():. PubMed ID: 39282957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
    Palmer A; Papaluca T; Stoové M; Winter R; Pedrana A; Hellard M; Wilson D; Thompson A; Scott N;
    Int J Drug Policy; 2021 Aug; 94():103203. PubMed ID: 33744667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons.
    Sheehan Y; Cochrane A; Treloar C; Grebely J; Tedla N; Lloyd AR; Lafferty L
    Int J Drug Policy; 2024 Aug; 130():104516. PubMed ID: 38996643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
    Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
    Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
    Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
    Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
    Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
    BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
    Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
    Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.
    Hale AJ; Mathur S; Dejace J; Lidofsky SD
    Public Health Rep; 2023; 138(2):265-272. PubMed ID: 35264027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
    Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
    BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.